Advanced

Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15–34 years of age: a prospective cohort study

Samuelsson, My; Dereke, Jonatan LU ; Svensson, Maria K.; Landin-Olsson, Mona LU and Hillman, Magnus LU (2017) In Diabetology and Metabolic Syndrome 9(1). p.1-6
Abstract
Background
The aim of this study was to investigate plasma levels of sST2 and sCD163 to determine whether they at an early stage could predict development of diabetic nephropathy and/or diabetic retinopathy in patients at clinical onset.

Methods
Patients diagnosed with diabetes mellitus at age 15–34 years between 1987 and 1988 (n = 220) were included. Data such as BMI, smoking, HbA1c and islet cell antibodies were collected at time of diagnosis. Within the 10 year follow-up period, 112 patients (51%) developed following diabetes related complications; retinopathy (n = 91), nephropathy (n = 12) or both (n = 9). Plasma concentrations of sST2 and sCD163 were measured at time of diagnosis and levels compared between different... (More)
Background
The aim of this study was to investigate plasma levels of sST2 and sCD163 to determine whether they at an early stage could predict development of diabetic nephropathy and/or diabetic retinopathy in patients at clinical onset.

Methods
Patients diagnosed with diabetes mellitus at age 15–34 years between 1987 and 1988 (n = 220) were included. Data such as BMI, smoking, HbA1c and islet cell antibodies were collected at time of diagnosis. Within the 10 year follow-up period, 112 patients (51%) developed following diabetes related complications; retinopathy (n = 91), nephropathy (n = 12) or both (n = 9). Plasma concentrations of sST2 and sCD163 were measured at time of diagnosis and levels compared between different complication groups.

Results
Plasma levels of sST2 were significantly higher in patients who later developed nephropathy (n = 21; 1012 [773–1493] pg/ml) compared to those who did not (n = 199; 723 [449–1084] pg/ml; p = 0.006). A tendency for higher plasma levels of sCD163 was observed but not statistically significant (p = 0.058).

Conclusions
sST2 and sCD163 show promise as potential biomarkers for the development of nephropathy already at clinical onset. sST2 and/or sCD163 could possibly be part of a biomarker panel aimed to find patients at high risk of developing nephropathy. Both markers need to be investigated in a larger prospective study. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, complications, diabetes, nephropathy
in
Diabetology and Metabolic Syndrome
volume
9
issue
1
pages
1 - 6
publisher
BioMed Central
external identifiers
  • scopus:85019689708
  • wos:000402149200001
ISSN
1758-5996
DOI
10.1186/s13098-017-0240-2
language
English
LU publication?
yes
id
57441ca9-ddeb-4fe4-9778-82fa43738e31
date added to LUP
2017-06-18 13:41:41
date last changed
2017-09-18 11:41:50
@article{57441ca9-ddeb-4fe4-9778-82fa43738e31,
  abstract     = {Background<br/>The aim of this study was to investigate plasma levels of sST2 and sCD163 to determine whether they at an early stage could predict development of diabetic nephropathy and/or diabetic retinopathy in patients at clinical onset.<br/><br/>Methods<br/>Patients diagnosed with diabetes mellitus at age 15–34 years between 1987 and 1988 (n = 220) were included. Data such as BMI, smoking, HbA1c and islet cell antibodies were collected at time of diagnosis. Within the 10 year follow-up period, 112 patients (51%) developed following diabetes related complications; retinopathy (n = 91), nephropathy (n = 12) or both (n = 9). Plasma concentrations of sST2 and sCD163 were measured at time of diagnosis and levels compared between different complication groups.<br/><br/>Results<br/>Plasma levels of sST2 were significantly higher in patients who later developed nephropathy (n = 21; 1012 [773–1493] pg/ml) compared to those who did not (n = 199; 723 [449–1084] pg/ml; p = 0.006). A tendency for higher plasma levels of sCD163 was observed but not statistically significant (p = 0.058).<br/><br/>Conclusions<br/>sST2 and sCD163 show promise as potential biomarkers for the development of nephropathy already at clinical onset. sST2 and/or sCD163 could possibly be part of a biomarker panel aimed to find patients at high risk of developing nephropathy. Both markers need to be investigated in a larger prospective study.},
  articleno    = {41},
  author       = {Samuelsson, My and Dereke, Jonatan and Svensson, Maria K. and Landin-Olsson, Mona and Hillman, Magnus},
  issn         = {1758-5996},
  keyword      = {biomarkers,complications,diabetes,nephropathy},
  language     = {eng},
  month        = {05},
  number       = {1},
  pages        = {1--6},
  publisher    = {BioMed Central},
  series       = {Diabetology and Metabolic Syndrome},
  title        = {Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15–34 years of age: a prospective cohort study},
  url          = {http://dx.doi.org/10.1186/s13098-017-0240-2},
  volume       = {9},
  year         = {2017},
}